Home

CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $182.5 million in 55 projects around the world.

182.5

$million

Invested

55

innovative

Projects

7

different

Countries

15

focused on new classes

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

SutroVax’s new vaccine could be a game-changer in the prevention of Strep Throat infections and the spread of superbugs

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners

Events

Events

CARB-X News

  • 01.13.2020  |  CARB-X funds Trellis Bioscience to support the development of a monoclonal antibody designed to disrupt superbugs’ protective coating so that antibiotics can kill them full release

  • 01.08.2020  |  CARB-X funds TAXIS Pharmaceuticals to accelerate development of innovative efflux pump inhibitors (EPIs), a new drug class that would impair bacteria’s ability to fight antibiotics full release

  • 01.07.2020  |  CARB-X backs Centauri to advance a new platform that combines antibiotic power with the ability to boost the immune system to fight infections caused by drug-resistant bacteria full release

See All News

In The News

  • 01.17.2020  |  Novel Drug Candidate Aims To Tackle Superbug Infections In Cystic Fibrosis Patients full story

  • 01.08.2020  |  Antabio continues research for lung infection therapy with $4.4 million support from CARB-X full story

  • 01.05.2020  |  Antibiotic Makers Struggle, Hurting War on Superbugs full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.